| Characterization of nanoparticle uptake by endothelial cells J Davda, V Labhasetwar International journal of pharmaceutics 233 (1-2), 51-59, 2002 | 681 | 2002 |
| The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers MG Qaddoumi, H Ueda, J Yang, J Davda, V Labhasetwar, VHL Lee Pharmaceutical research 21, 641-648, 2004 | 320 | 2004 |
| Long-acting MIC-1/GDF15 molecules to treat obesity: evidence from mice to monkeys Y Xiong, K Walker, X Min, C Hale, T Tran, R Komorowski, J Yang, J Davda, ... Science translational medicine 9 (412), eaan8732, 2017 | 196 | 2017 |
| Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis MG Qaddoumi, HJ Gukasyan, J Davda, V Labhasetwar, KJ Kim, VH Lee Mol Vis 9, 559-568, 2003 | 190 | 2003 |
| Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics J Davda, P Declerck, S Hu-Lieskovan, TP Hickling, IA Jacobs, J Chou, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 122 | 2019 |
| A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs JP Davda, M Jain, SK Batra, PR Gwilt, DH Robinson International immunopharmacology 8 (3), 401-413, 2008 | 116 | 2008 |
| Pharmacokinetic and Biodistribution Studies of a Bone-Targeting Drug Delivery System Based on N-(2-Hydroxypropyl)methacrylamide Copolymers D Wang, M Sima, RL Mosley, JP Davda, N Tietze, SC Miller, PR Gwilt, ... Molecular pharmaceutics 3 (6), 717-725, 2006 | 100 | 2006 |
| Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets JP Davda, RJ Hansen MAbs 2 (5), 576-588, 2010 | 83 | 2010 |
| Selective serotonin depletion does not regulate hippocampal neurogenesis in the adult rat brain: differential effects of p-chlorophenylalanine and 5, 7-dihydroxytryptamine S Jha, R Rajendran, J Davda, VA Vaidya Brain research 1075 (1), 48-59, 2006 | 72 | 2006 |
| Assessment of subcutaneous vs intravenous administration of anti–PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial ML Johnson, F Braiteh, JE Grilley-Olson, J Chou, J Davda, A Forgie, R Li, ... JAMA oncology 5 (7), 999-1007, 2019 | 54 | 2019 |
| A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design JP Davda, MG Dodds, MA Gibbs, W Wisdom, JP Gibbs mAbs 6 (4), 1094-1102, 2014 | 38 | 2014 |
| Assessing the acceptability, reliability, and validity of the EORTC Quality of Life Questionnaire (QLQ-C30) in Kenyan cancer patients: a cross-sectional study J Davda, H Kibet, E Achieng, L Atundo, T Komen Journal of Patient-Reported Outcomes 5, 1-8, 2021 | 25 | 2021 |
| C5-alkyl-2-methylurea-substituted pyridines as a new class of glucokinase activators X Du, RJ Hinklin, Y Xiong, P Dransfield, J Park, TJ Kohn, V Pattaropong, ... ACS Medicinal Chemistry Letters 5 (12), 1284-1289, 2014 | 17 | 2014 |
| Sustained proangiogenic activity of vascular endothelial growth factor following encapsulation in nanoparticles J Davda, V Labhasetwar Journal of Biomedical Nanotechnology 1 (1), 74-82, 2005 | 17 | 2005 |
| An update on angiogenesis therapy J Davda, V Labhasetwar Critical Reviews™ in Eukaryotic Gene Expression 11 (1-3), 2001 | 13 | 2001 |
| Uptake of biodegradable nanoparticles in pigmented rabbit conjunctival epithelial cells MG Qaddoumi, H Ueda, J Yang, J Davda, V Labhasetwar, VHL Lee Investigative Ophthalmology & Visual Science 41 (4), 4054B1, 2000 | 7 | 2000 |
| The mechanism of uptake of biodegradable PLGA nanoparticles in conjunctival epithelial cell layers. MG Qaddoumi, H Ueda, J Yang, J Davda, V Labhasetwar, VHL Lee INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42 (4), S487-S487, 2001 | 4 | 2001 |
| Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours G Baheti, TR McGuire, JP Davda, KK Manouilov, D Wall, PR Gwilt, ... Xenobiotica 43 (3), 276-282, 2013 | 3 | 2013 |
| Safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC) S Hu-Lieskovan, M Johnson, FS Braiteh, J Grilley-Olson, J Chou, J Davda, ... Annals of Oncology 28, v419, 2017 | 2 | 2017 |
| Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics J Davda, K Reynolds, JD Davis, PF Smith British Journal of Clinical Pharmacology 87 (9), 3398-3407, 2021 | 1 | 2021 |
